11-11-15 $CTIX ~ Cellceutix Corp. due diligence report from

New Post Public Reply Private Reply Replies (0) Message Board
TheHound
11-11-15 $CTIX ~ Cellceutix Corp. due diligence report from -TheHound- Go CTIX!



$CTIX recent news


Press releases from Cellceutix:

http://cellceutix.com/category/press-release/...r967e.dpbs


PR's from Yahoo:

Wed, 11 Nov 2015 15:34:21 GMT ~ Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to report that ...

read full: http://finance.yahoo.com/news/cellceutix-comp...21863.html


Tue, 10 Nov 2015 15:51:02 GMT ~ Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report ...

read full: http://finance.yahoo.com/news/cellceutix-file...02882.html


Mon, 09 Nov 2015 21:13:18 GMT ~ CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report

read full: http://biz.yahoo.com/e/151109/ctix10-q.html


Tue, 03 Nov 2015 22:26:56 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statem

read full: http://biz.yahoo.com/e/151103/ctix8-k.html


Fri, 30 Oct 2015 17:00:10 GMT ~ Cellceutix aims for late-stage trial of antibiotic next year

read full: http://www.bizjournals.com/boston/blog/biofla...?ana=yahoo


Fri, 30 Oct 2015 12:17:00 GMT ~ How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked ...

read full: http://finance.yahoo.com/news/plays-research-...00619.html


Fri, 30 Oct 2015 11:30:00 GMT ~ Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide an update ...

read full: http://finance.yahoo.com/news/cellceutix-prov...00865.html


Mon, 26 Oct 2015 12:34:00 GMT ~ Cellceutix Due Diligence Report: False Accusations Cause Mayhem; Share Price Ready to Bounce

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Cellceutix Corp. (OTCMKTS: CTIX) a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, ...

read full: http://finance.yahoo.com/news/cellceutix-due-...00041.html


Mon, 26 Oct 2015 11:40:04 GMT ~ Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders ...

read full: http://finance.yahoo.com/news/cellceutix-requ...04556.html


Thu, 22 Oct 2015 18:28:15 GMT ~ Cellceutix Responds to Rosen Law Firm

[Marketwired] - Cellceutix Corporation , Cellceutix was created to tackle some of the worst diseases known to man. We are a company that firmly believes in the strength of our science and technology. It is our science ...

read full: http://finance.yahoo.com/news/cellceutix-resp...15404.html


$CTIX filings - Perhaps the most important section.

http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany



$CTIX charts

basic chart ## source: stockscores.com





$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA

Business Description: Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. This trial just completed it's final cohort . Plans for a Ph 2/3 Ovarian Cancer Study are underway. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is currently conducting a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, recently completed a successful Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Plans for a phase 3 trial are underway w/ FDA's approval. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Please click on the below link to find for more information on completed and active Human Clinical Trials.


https://www.clinicaltrials.gov/ct2/results?te...rch=Search




$CTIX share structure

## source: otcmarkets.com

Market Value: $153,621,697 a/o Nov 10, 2015
Shares Outstanding: 118,170,536 a/o Aug 26, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001



$CTIX extra dd links

Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com

## STOCK DETAILS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CTIX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CTIX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CTIX+Industry

## COMPANY NEWS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/news - http://finance.yahoo.com/q/h?s=CTIX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CTIX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CTIX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CTIX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cellceutix+Corp.&a...ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&am...eutix+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results...=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cellceutix.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cellceutix.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cellceutix.com

## FUNDAMENTALS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/compa...yword/CTIX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/financials?...-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?...rch=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CTIX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CTIX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CTIX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CTIX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CTIX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CTIX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CTIX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CTIX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CTIX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CTIX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CTIX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/st...icker=CTIX



1) UPCOMING MILESTONES / CATALYSTS

SCIENCE:

- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)

OPERATIONS:

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

2) CURRENT TRIALS:

Clinical Trials

Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1

2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4

4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5

Abbreviations:

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
http://www.cellceutix.com

**This section courtesy of Slcimmuno - Thanks brother!**

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duke Energy Braces for Isaias: Key Prep Steps Ahead

Updated Category News Views 6

Brace Yourself: Duke Energy Gears Up for Isaias In the ever-unpredictable game of Mother Nature versus infrastructure, Duke Energy is stepping into the ring once more, readying to tackle potential outages across the Carolinas as Hurricane Isaias edges near. Listen, if there's one thing I've learned over years of watching these weather events unfold on the stock ticker and...

Continue Reading
TKO's Bold $2B All-Cash Move for SVC's Hotels

Updated Category News Views 5

TKO's Big, Bold Bid: What Does it Mean? In the crazy world of high-stakes hospitality investments, there are moments that turn heads. TKO's $2 billion all-cash offer to snag Service Properties Trust's prized hotel portfolio is exactly one of those shake-ups. Let's not sugarcoat it; this is a bold move to the big leagues, and it's not without its quirks. A Cash-Infused...

Continue Reading
BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 3

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
HackerOne Finds Cybersecurity Challenges in Exposure Debt

Updated Category News Views 14

Understanding the Implications of 'Exposure Debt' When you hear about 'exposure debt', it's not just tech jargon—it's a core issue hacking at the very safety nets companies rely on. This term, highlighted in HackerOne's latest Security Research Report, marks a stark reality in cybersecurity. The backlog of verified yet unresolved vulnerabilities surged a whopping 131%...

Continue Reading
Moore, Schulman & Moore Attorneys Earn Top Honors Again

Updated Category News Views 4

In the realm of family law, consistency in excellence matters just as much as landing a high-stakes stock trade. Moore, Schulman & Moore, APC, a San Diego family law outfit, has grabbed the spotlight yet again with nine of its ace attorneys snagging recognition from the 2027 Super Lawyers roster. A Tradition of Professional Recognition Leading the pack is Erik Moore, a...

Continue Reading
STRATA Showcases Excimer Laser Success in Dermatology

Updated Category News Views 4

The Cutting Edge of Skin Care: STRATA's Spotlight It's not every day you hear about dermatology shaking things up, but STRATA Skin Sciences, Inc. pulled it off with flair at the 2026 Fall Clinical Dermatology Conference in Las Vegas. For 'skin in the game,' these folks are leading the charge with their innovative excimer laser phototherapy approach, shining a fresh light...

Continue Reading
Mastering Packaging Costs: Beyond the Box Price

Updated Category News Views 4

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Continue Reading
Bill Evans Enhances Gateway's Wealth Management Expertise

Updated Category News Views 5

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...

Continue Reading
AI Visibility: A Game Changer for SEO in 2027?

Updated Category News Views 5

AI Changes the SEO Game Rank Math, the brains behind a trusty WordPress SEO plugin, has thrown a bold prediction at us: AI visibility is set to become a standard SEO metric next year. Gurugram, India, saw this gem of an announcement on October 9, 2026. So, what's ticking here? Consumers, more than ever, are resting on AI-generated answers to make decisions. It's like...

Continue Reading
Zenni and Chase Stokes Foster Student Wellbeing in NYC

Updated Category News Views 3

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

Continue Reading

Top 5 Most Recently Viewed Articles

Envoy Expands EV Car-Sharing Service in Luxury Miami Project

Updated Category News Views 254

Envoy Launches EV Car-Sharing Service at Forma Miami Envoy Technologies Inc. is excited to announce its new electric vehicle (EV) car-sharing service at Forma Miami Residences, a luxurious residential community developed by Crescent Heights. This launch marks the first collaboration between Envoy and Crescent Heights, highlighting the expansion of Envoy’s innovative...

Continue Reading
Global Ultra-High Performance Concrete Market Insights Through 2032

Updated Category News Views 41

Overview of the Ultra-High Performance Concrete Market Allied Market Research has presented a comprehensive report on the ultra-high performance concrete (UHPC) market. The market, valued at approximately $629 million in recent years, is projected to soar to an impressive $1,048.2 million by the end of the forecast period, reflecting a robust compound annual growth rate...

Continue Reading
SEMI's Cybersecurity Initiative Aims to Enhance Protection

Updated Category News Views 245

Advancements in Semiconductor Cybersecurity by SEMI The SEMI Semiconductor Manufacturing Cybersecurity Consortium (SMCC), in collaboration with the National Institute of Standards and Technology (NIST), has taken a significant step toward improving cybersecurity measures across the semiconductor manufacturing sector. This initiative aims to solidify a community profile...

Continue Reading
Ladybird Jet Launches New Shuttle Service for Regional Travel

Updated Category News Views 259

Ladybird Jet Introduces a New Era in Regional Travel Ladybird Jet has officially announced the launch of its premium air shuttle service, marking a significant milestone in the realm of regional travel. This innovative service aims to cater to travelers who seek comfort, efficiency, and hassle-free journeys within Texas. Co-founded by Michele Wilkinson and Devon Perry,...

Continue Reading
Digital Asset Technologies Invites Investment in Future Finance

Updated Category News Views 116

Digital Asset Technologies Proposes $3 Million Private Placement Digital Asset Technologies Inc. (CSE: DATT) is excited to announce a new initiative that aims to bolster its innovative projects. The Company is planning a non-brokered private placement offering of up to 3,000 convertible debenture units, priced at C$1,000 each. This strategic move is set to potentially...

Continue Reading